OM1 has deployed a new artificial intelligence-driven platform to provide personalized information on diagnosis, treatment, risk, use and clinical trials.
Called PhenOM, the platform is calibrated using OM1’s long-term health history database, which contains data from over 300 million patients.
PhenOM leverages AI to recognize specific digital phenotypes associated with conditions and outcomes, and compare patient records against them to highlight risks and options.
It can provide customized healthcare inputs across the healthcare ecosystem, including life science research and point-of-care clinical decision-making.
In addition, PhenOM collects details from vast patient data sets, such as unstructured clinical notes and disease activity indices, to isolate patient-specific patterns.
The platform integrates these patterns into specific digital phenotypes or ‘fingerprints’.
These phenotypes will be evaluated to support research and deployed to real-world datasets inside and outside OM1, via healthcare systems and other patient-facing web portals.
Dr. Joseph Zabinski, Managing Director, OM1 AI and Personalized Medicine, said:
“PhenOM is a breakthrough technology that uses AI to transform actionable insights from highly enriched datasets and phenotyping technology into more personalized healthcare opportunities.
“This capability has the potential to significantly impact all stakeholders, from identifying patients with underdiagnosed conditions, to enabling personalized benefit assessments for specific therapies, to accelerating enrollment in clinical trials. It creates sex.”
